Skip to main content

Advertisement

SpringerLink
Log in

Population-Based Analysis of Completion Lymphadenectomy in Intermediate-Thickness Melanoma

  • Melanomas
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Multicenter selective lymphadenectomy trial 1 (MSLT-I) defined the prognostic and potential therapeutic values of sentinel lymph node biopsy (SLNB) for intermediate-thickness melanoma. The role of completion lymphadenectomy (CLND) is, however, unclear and the subject of the ongoing MSLT-II trial.

Methods

From 2003 to 2012, patients with tumors 1–4 mm thick with positive SLNB were identified in the Surveillance Epidemiology and End Results Program registry. The patients were divided into two groups: group 1 (CLND) and group 2 (observation).

Results

The study enrolled 2172 patients, the majority of whom were white and male with extremity primaries, no ulceration, Clark level 4 invasion, and nodes 2.01–4.0 mm deep. In the univariate analysis, CLND was associated with lower mean age, male gender, primary site, number of positive nodes, and geographic region (p < 0.05). In the multivariate analysis, male gender [odds ratio (OR), 1.27] and geographic area (Michigan OR, 2.31; Iowa OR, 1.69) were associated with CLND (p < 0.05). In the survival analysis, male gender, primary site, ulceration, Clark level, and depth and number of positive nodes were associated with survival (p < 0.05), but CLND was not (p = 0.83). In the Cox regression analysis, the relationship between male gender [hazard ratio (HR), 1.14], primary site trunk versus extremity (HR, 1.3), ulceration (HR, 1.79), Clark level (2 vs. 4 HR, 3.51; 2 vs. 5 HR, 6.48), depth (HR, 1.43) and number of nodes (1 vs. 2: HR, 1.23; 1 vs. ≥3: HR, 2.52) persisted (p < 0.05). However, when CLND was included in this model, it was not associated with improved survival.

Conclusions

Age, gender, and geographic area predict the likelihood of CLND. In this retrospective study, CLND did not add survival benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Neuhaus SJ, Clark MA, Thomas JM. Dr. Herbert Lumley Snow, MD, MRCS (1847–1930): the original h-vchampion of elective lymph node dissection in melanoma. Ann Surg Oncol. 2004;11:875–8. doi: 10.1245/ASO.2004.02.031.

    Article  PubMed  Google Scholar 

  2. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242:302–11. discussion 311–3.

    PubMed  PubMed Central  Google Scholar 

  3. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial: WHO melanoma programme. Lancet. 1998;351:793–6.

    Article  CAS  PubMed  Google Scholar 

  4. Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7:87–97.

    Article  CAS  PubMed  Google Scholar 

  5. Wong JH, Cagle LA, Morton DL. Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann Surg. 1991;214:637–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early-stage melanoma. Arch Surg. 1992;127:392–9.

    Article  CAS  PubMed  Google Scholar 

  7. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609. doi: 10.1056/NEJMoa1310460.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kachare SD, Brinkley J, Wong JH, Vohra NA, Zervos EE, Fitzgerald TL. The influence of sentinel lymph node biopsy on survival for intermediate-thickness melanoma. Ann Surg Oncol. 2014;21:3377–85. doi: 10.1245/s10434-014-3954-5.

    Article  PubMed  Google Scholar 

  9. Wong SL, Morton DL, Thompson JF, et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol. 2006;13:809–16. doi: 10.1245/ASO.2006.03.058.

    Article  PubMed  Google Scholar 

  10. Fritsch VA, Cunningham JE, Lentsch EJ. Completion lymph node dissection based on risk of nonsentinel metastasis in cutaneous melanoma of the head and neck. Otolaryngol Head Neck Surg. 2016;154(1):94–104.

    Article  PubMed  Google Scholar 

  11. Bamboat ZM, Konstantinidis IT, Kuk D, Ariyan CE, Brady MS, Coit DG. Observation after a positive sentinel lymph node biopsy in patients with melanoma. Ann Surg Oncol. 2014;21:3117–23. doi: 10.1245/s10434-014-3758-7.

    Article  PubMed  Google Scholar 

  12. Kingham TP, Panageas KS, Ariyan CE, Busam KJ, Brady MS, Coit DG. Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy. Ann Surg Oncol. 2010;17:514–20. doi: 10.1245/s10434-009-0836-3.

    Article  PubMed  PubMed Central  Google Scholar 

  13. van der Ploeg AP, van Akkooi AC, Haydu LE, et al. The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. Eur J Cancer. 2014;50:111–20. doi: 10.1016/j.ejca.2013.08.023.

    Article  PubMed  Google Scholar 

  14. National Comprehensive Cancer Network, Inc. NCCN Guidelines Version 2.2016 Melanoma. http://www.refworks.com/refworks2/default.aspx?r=references|MainLayout::init (2015). Accessed 26 Apr 2016. Updated 11/25/2015.

  15. Dzwierzynski WW. Complete lymph node dissection for regional nodal metastasis. Clin Plast Surg. 2010;37:113–25. doi: 10.1016/j.cps.2009.07.002.

    Article  PubMed  Google Scholar 

  16. Bilimoria KY, Balch CM, Bentrem DJ, et al. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the united states. Ann Surg Oncol. 2008;15:1566–76. doi: 10.1245/s10434-008-9885-2.

    Article  PubMed  Google Scholar 

  17. Morton DL. Overview and update of the phase III multicenter selective lymphadenectomy trials (MSLT-I and MSLT-II) in melanoma. Clin Exp Metastasis. 2012;29:699–706. doi: 10.1007/s10585-012-9503-3.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Surveillance Research Program. http://seer.cancer.gov/. Accessed 9 Nov 2015.

  19. Kretschmer L, Thoms KM, Peeters S, Haenssle H, Bertsch HP, Emmert S. Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection. Melanoma Res. 2008;18:16–21. doi: 10.1097/CMR.0b013e3282f2017d.

    Article  PubMed  Google Scholar 

  20. Roaten JB, Pearlman N, Gonzalez R, Gonzalez R, McCarter MD. Identifying risk factors for complications following sentinel lymph node biopsy for melanoma. Arch Surg. 2005;140:85–9.

    Article  PubMed  Google Scholar 

  21. van der Ploeg AP, van Akkooi AC, Rutkowski P, et al. Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection. Br J Surg. 2012;99:1396–405. doi: 10.1002/bjs.8878.

    Article  PubMed  Google Scholar 

  22. Fritsch VA, Cunningham JE, Lentsch EJ. Completion lymph node dissection based on risk of nonsentinel metastasis in cutaneous melanoma of the head and neck. Otolaryngol Head Neck Surg. 2016;154:94–103. doi: 10.1177/0194599815605494.

    Article  PubMed  Google Scholar 

  23. Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016.

    Article  PubMed  Google Scholar 

Download references

Disclosure

There are no conflicts of interest.

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, East Carolina University Brody School of Medicine, Greenville, NC, USA

    Catalina Mosquera MD, Nasreen Vohra MD & Timothy L. Fitzgerald MD

  2. East Carolina University Brody School of Medicine, Greenville, NC, USA

    Haily S. Vora BS

Authors
  1. Catalina Mosquera MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haily S. Vora BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nasreen Vohra MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Timothy L. Fitzgerald MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy L. Fitzgerald MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mosquera, C., Vora, H.S., Vohra, N. et al. Population-Based Analysis of Completion Lymphadenectomy in Intermediate-Thickness Melanoma. Ann Surg Oncol 24, 127–134 (2017). https://doi.org/10.1245/s10434-016-5460-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-016-5460-4

Keywords

Search

Navigation